Retrospective Medical Chart Review Study for Non-valvular Atrial Fibrillation Patients Treated or Untreated With Oral Anticoagulant in the National Cerebral and Cardiovascular Center (NCVC) in Japan
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Non-Valvular Atrial Fibrillation (NVAF)
- Sponsor
- Bristol-Myers Squibb
- Enrollment
- 11776
- Locations
- 1
- Primary Endpoint
- Distribution of outcomes of NVAF participants: Smoking information
- Status
- Completed
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this observational study is to understand real-world oral anticoagulants (OAC) (warfarin, apixaban, dabigatran, edoxaban and rivaroxaban) usage for non-valvular atrial fibrillation (NVAF) patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Participants received medical treatment for NVAF between 10-Jan-2012 and 31-Aug-2020.
Exclusion Criteria
- •Had no data of serum creatinine in the participant's medical records
- •Had no data of body weight in the participant's medical records
- •Were given oral anticoagulant (OAC) for treatment of diseases other than atrial fibrillation (AF)
- •Other protocol-defined inclusion/exclusion criteria apply.
Outcomes
Primary Outcomes
Distribution of outcomes of NVAF participants: Smoking information
Time Frame: At Baseline
Distribution of outcomes of NVAF participants: Pulse rate
Time Frame: At Baseline
Distribution of socio-demographic characteristics of NVAF participants: Age group
Time Frame: At Baseline
Distribution of socio-demographic characteristics of NVAF participants: Height
Time Frame: At Baseline
Distribution of outcomes of NVAF participants: Degree of life freedom
Time Frame: At Baseline
Distribution of clinical characteristics of NVAF participants: Risk factors for bleeding
Time Frame: At Baseline
Distribution of medication prescribed during baseline: angiotensin-converting enzyme inhibitor (ACE)
Time Frame: At Baseline
Distribution of medication prescribed during baseline: Antiarrhythmic drug
Time Frame: At Baseline
Distribution of medication prescribed during baseline: H2-receptor antagonist
Time Frame: At Baseline
Distribution of clinical characteristics of NVAF participants: Comorbidities
Time Frame: At Baseline
Specialization of the treating physician
Time Frame: At Baseline
Distribution of socio-demographic characteristics of NVAF participants: Gender
Time Frame: At Baseline
Distribution of outcomes of NVAF participants: Systolic and diastolic blood pressure
Time Frame: At Baseline
Distribution of medication prescribed during baseline: angiotensin-receptor blocker (ARB)
Time Frame: At Baseline
Distribution of outcomes of NVAF participants: Hospitalization/outpatient status
Time Frame: At Baseline
Distribution of socio-demographic characteristics of NVAF participants: Body weight
Time Frame: At Baseline
Distribution of outcomes of NVAF participants: Drinking information
Time Frame: At Baseline
Distribution of clinical characteristics of NVAF participants: Risk factors for stroke
Time Frame: At Baseline
Distribution of outcomes of NVAF participants: OAC prescription and administration status
Time Frame: At Baseline
Distribution of medication prescribed during baseline: Statin
Time Frame: At Baseline
Distribution of medication prescribed during baseline: P2Y12 inhibitor
Time Frame: At Baseline
Distribution of medication prescribed during baseline: Other antiplatelet drugs
Time Frame: At Baseline
Distribution of medication prescribed during baseline: Other anticoagulants
Time Frame: At Baseline
Distribution of socio-demographic characteristics of NVAF participants: Body mass index (BMI)
Time Frame: At Baseline
Distribution of outcomes of NVAF participants: Internal medical device information
Time Frame: At Baseline
Distribution of medication prescribed during baseline: calcium antagonist
Time Frame: At Baseline
Distribution of medication prescribed during baseline: proton pump inhibitor (PPI)
Time Frame: At Baseline
Distribution of medication prescribed during baseline: aspirin
Time Frame: At Baseline
Distribution of medication prescribed during baseline: P-glycoprotein inhibitor
Time Frame: At Baseline